Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity

Diabetes and Vascular Disease Research

Volumn 4, Issue 3, 2007, Pages 163-173

  Marre, Michel ^a,b,c   Leye, Abdoulaye ^a,d  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d Centre Hospitalier Universitaire Aristide Le Dantec de Dakar   (Senegal)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Hypertension; Insulin resistance

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; LOSARTAN; NIFEDIPINE; PERINDOPRIL; POTASSIUM; THIAZIDE DIURETIC AGENT;

ABSENCE OF SIDE EFFECTS; ATHEROSCLEROSIS; BRAIN TISSUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; ESSENTIAL HYPERTENSION; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; INCIDENCE; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA BLOOD FLOW; REVIEW; RISK FACTOR; STROKE; TREATMENT DURATION; TREATMENT OUTCOME; VASCULARIZATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MODELS, BIOLOGICAL; PERINDOPRIL;

EID: 34948843472     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2007.037     Document Type: Review

References (90)

1. Julius S, Majahalme S, Palatini P. Antihypertensive treatment of patients with diabetes and hypertension. Am J Hypertens 2001;14(suppl): 310-16.
2. Fogari R, Mugellini A, Zoppi A et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002;15:316-20.
3. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens 2005;23(suppl 1):9-17.
4. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003;91(suppl):30H-37H.
5. Sjöholm A, Nyström T. Endothelial inflammation in insulin resistance. Lancet 2005;365:610-12.
6. Morganti A. Should a diuretic always be the first choice in patients with essential hypertension? The case for no. J Am Soc Nephrol 2005;16 (suppl 1):S70-S73.
7. Sharma AM, Janke J, Gorzelniak K et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002;40:609-11.
8. Hsueh WA, Law RE. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med 1998;105(suppl):4-14.
9. Tikellis C, Wookey PJ, Candido R et al. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004;53:989-97.
10. Ingelfinger JR, Solomon CG. Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance - is there still hope? N Engl J Med 2006; 355:1608-10.
11. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004;22:1453-8.
12. Andersen NH, Poulsen SH, Poulsen PL et al. Left ventricular dysfunction in hypertensive patients with type 2 diabetes mellitus. Diabet Med 2005;22:1218-25.
13. Salmasi AM, Dancy M. Glucose intolerance: the hidden danger in hypertensives! Int Angiol 2005;24:207-14.
14. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006;24:11-25.
15. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:263-72.
16. Cordonnier DJ, Pinel N, Barro C et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. J Am Soc Nephrol 1999;10:1253- 63.
17. McLennan SV, Kelly DJ, Cox AJ et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002;45:268-75.
18. Erensoy N, Yilmazer S, Öztürk M et al. Effects of ACE inhibition on the expression of type IV collagen and laminin in renal glomeruli in experimental diabetes. Acta Histochemica 2004;106:279-87.
19. Hsieh T-J, Fustier P, Wei C-C et al. Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells. J Endocrinol 2004;183:535-50.
20. Adachi H, Hirai Y, Tsuruta M et al. Is insulin resistance or diabetes mellitus associated with stroke? An 18-year follow-up study. Diabetes Res Clin Pract 2001;51:215-23.
21. Soucek M. Diabetes mellitus cerebrovascular disease. Vnitr Lek 2003; 49:916-20.
22. Jovanovic-Peterson L, Peterson CM. Diabetic retinopathy. Clin Obstet Gynecol 1991;34:516-25.
23. Patel V, Rassam SMB, Chen HC et al. Effect of angiotensin- converting enzyme inhibition with perindopril and beta-blockade with atenolol on retinal blood flow in hypertensive diabetic subjects. Metabolism 1998; 47(suppl 1):28-33.
24. Lithell HO, Pollare, Berne C. Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 1990;15(suppl 5):S46-S52.
25. Bak JF, Gerdes LU, Sorensen NS, Pedersen O. Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. Am J Med 1992;92(4B):69S- 72S.
26. Jandrain B, Herbaut C, Depoorter J-C, Vd Voorde K. Long-term (1 year) acceptability of perindopril in type II diabetic patients with hypertension. Am J Med 1992;92(suppl 4B):91-4.
27. Messerli FH, Grossman E, Leonetti C. Antihypertensive therapy and new-onset diabetes. J Hypertens 2004;22:1845-7.
28. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of β-blocking agents? Am J Hypertens 1998;11:1258-65.
29. Verdecchia P, Reboldi C, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-9.
30. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006;29:1065-70.
31. Oksa A, Gajdos M, Fedelesova V et al. Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol 1994;23:79-86.
32. Gillespie EL, White CM, Kardas M et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005;28:2261-6.
33. Dagenais GR, Pogue U, Fox K, Simoons ML, Yusuf S. Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8.
34. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62.
35. Jandeleit-Dahm KAM, Tikellis C, Reid CM et al. Why blockade of the renin-angiotensin system reduced the incidence of new-onset diabetes. J Hypertens 2005;23:463-73.
36. Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76-81.
37. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998;41:127-33.
38. Tahmasebi M, Puddefoot JR, Inwang ER et al. The tissue renin-angiotensin system in human pancreas. J Endocrinol 1999;161:317-22.
39. Miyata T, Taguchi T, Uehara M et al. Bradykinin potentiates insulin-stimulated glucose uptake and enhances insulin signal through the bradykinin B2 receptor in dog skeletal muscle and rat L6 myoblasts. Eur J Endocrinol 1998;138:344-52.
40. Dietze GJ, Wcklmayr M, Rett K et al. Potential role of bradykinin in forearm muscle metabolism in humans. Diabetes 1996;45(suppl 1): S110-S114.
41. Rett K, Wicklmayr M, Dietze GJ et al. Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes 1996;45(suppl 1):S66-S69.
42. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23:439-49.
43. Fogari R, Zoppi A, Lazzari P et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovas Pharmacol 1998;32:616-20.
44. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting enzyme inhibitor ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
45. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-16.
46. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-97.
47. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multi-centre randomised controlled trial. Lancet 2005;366:895-906.
48. Brichard S, Ketelslegers JM, Lambert AE, Renal function, glycaemic control and perindopril in diabetic patients. Arch Mal Coeur 1989;82:57-61.
49. Derosa G, Cicero AFG, Ciccarelli L, Fogari R. A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther 2003;25:2006-21.
50. Jinxiu L, Daguang C, Kegui W et al. The effect of amlodipine, nifedipine and perindopril on insulin sensitivity and blood lipid of patients with essential hypertension (article in Chinese). Natl Med J China 1998;78: 200-02.
51. Uchida K, Azukizawa S, Kigoshi T et al. Effects of perindopril on glucose and lipid metabolism in patients with mild-to-moderate essential hypertension and glucose intolerance. Clin Ther 1994;16:466-70.
52. Stumpe KO, Overlack A. A new trial of the efficacy, tolerability, and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Perindopril Therapeutic Safety Study Group (PUTS). Am J Cardiol 1993;71:32E-37E.
53. Gupta A. Determinants of new-onset diabetes among hypertensive patients randomised in the ASCOT-BPLA trial [abstract]. Presented at the joint meeting of the World Congress of Cardiology/European Society of Cardiology; 2006 Sept 2-6; Barcelona, Spain.
54. Sever P. ASCOT subgroup analysis and recent update [oral presentation]. Presented at the 41st Annual Meeting of the European Association for the Study of Diabetes, 2005 Sept 10-15; Athens, Greece. Oral presentation available from URL: http://www.easd-lectures.org/athens/index.php?menu=thumbs&id=87 [Accessed 2006 Dec 7]
55. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005;23:1777-81.
56. Fressinaud P, Berrut G, Gallois H. Antihypertensive activity and acceptability based upon clinical and laboratory parameters of perindopril: chief results in 23,460 mild to moderate hypertension patients treated for 6 months in general practice (French). Ann Cardiol Angéiol 1993; 42:51-9.
57. Suraniti S, Berrut G, Marre M, Fressinaud P. Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients. Am J Cardiol 1993;71:28E-31E.
58. Julius S, Cohn JN, Neutel J et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J Clin Hypertens 2004;6: 10-17.
59. Yasuda, G, Hasegawa K, Kuji T et al. Perindopril effects on ambulatory blood pressure: relation to sympathetic nervous activity in subjects with diabetic nephropathy. Am J Hypertens 2004;17:14-20.
60. Daly CA, Fox KM, Remme WJ et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005;26:1369-78.
61. Ito A, Egashira K, Narishige T et al. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J 2002;66:811-15.
62. Cooper ME, Cao Z, Rumble JR et al. Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies. Metabolism 1998;47(suppl 1):24-7.
63. Girerd X, Giannattasio C, Moulin C et al. Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long term antihypertensive treatment: the PERICLES study. J Am Coll Cardiol 1998;31:1064-73.
64. Tropeano A-I, Boutouyrie P, Pannier B et al. Brachial pressure-independent reduction in carotid stiffness after long term angiotensin converting enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48:1-7.
65. Boutouyrie P, Tropeano AI, Asmar R et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002;39:10-15.
66. Laurent S, Boutouyrie R Asmar R et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-41.
67. Thybo NK, Stephens N, Cooper A et al. Efficacy of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995;25(4 Pt 1):474-81.
68. Marketou ME, Zacharis EA, Papadaki E et al. Angiotensin converting enzyme inhibitors improves myocardial adrenergic innervation disturbances in normotensive patients with diabetes type 11. J Am Coll Cardiol 2005;45(3 suppl A):261A.
69. Manolis AJ, Iraklianou S, Pittaras A et al. Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. Am J Hypertens 2005;18:18-22.
70. Zhou M, Zhong H-J, Wu X-Y. Changes of ultrastructure and function of the aortic endothelium in streptozocin-diabetic rats and effect of perindopril. Bull Hunan Med Univ 2001;26:41-4.
71. Liu S-K, Chen X, You J-L, Zhou M. Protective effect of perindopril on dysfunction of endothelium-dependent relaxation in diabetic rats. Bull Hunan Med Univ 2000;25:122-4.
72. Toblli JE, Cao G, DeRosa G et al. Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats. Am J Hypertens 2004;17:172-80.
73. Rumble JR, Komers R, Cooper ME. Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J Hypertens 1996;14:601-07.
74. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991;302:210-16.
75. Hermans MP, Brichard SM, Colin I et al. Long-term reduction of microalbuminuria after 3 years of angiotensin-converting enzyme inhibition of perindopril in hypertensive insulin-treated diabetic patients. Am J Med 1992;92(suppl 4B):102-07.
76. Langham RG, Kelly DJ, Thomson NM et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002;45:1572-6.
77. Nankervis A, Nicholls K, Kilmartin G et al. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Metabolism 1998;47(suppl 1):12-15.
78. White KE, Pinel N, Cordonnier DJ et al. Does ACE inhibition slow progression of glomerulopathy in patients with type 2 diabetes mellitus? Diabetic Med 2001;18:933-6.
79. Langham RG, Kelly DJ, Gow RM et al. Transforming growth factor-β in human diabetic nephropathy. Diabetes Care 2006;29:2670-5.
80. Hoy WE, Wang Z, Baker PRA, Kelly AM. Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. Kidney Int 2005;98(suppl):76-82.
81. Kvetny J, Gregersen G, Smith Pedersen R. Randomized, placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. Q J Med 2001;94:89-94.
82. Jerums G, Allen TJ, Campbell DJ et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001;37:890-9.
83. Jerums G, Allen TJ, Campbell DJ et al. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with type 2 diabetes and microalbuminuria. Diabetic Med 2004;21:1192-9.
84. Duggan KA, Hodge G, Makarious MM, Charlesworth JA. Renoprotective differences between perindopril and enalapril in the diabetic hypertensive rat do not reflect glomerular angiotensin-converting enzyme activity. Clinical Science 1998;94:511-16.
85. Kelly DJ, Stein-Oakley J, Zhang Y et al. Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2)27 rats: attenuation with renin-angiotensin blockade. Nephrology 2004;9:7-13.
86. Yan L, Yang R, Cheng H et al. Protective effect of the angiotensin-converting enzyme inhibitor perindopril on diabetic glomerulopathy in streptozocin-induced diabetic rats. Chinese Med J 1998;111:306- 08.
87. Velasquez MT, Striffler JS, Abraham A et al. Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat. Hypertension 1997;30:1232-7.
88. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
89. Fox KM, EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
90. Chalmers J, Perkovic V, Joshi R et al. ADVANCE: breaking new ground in type 2 diabetes. J Hypertens Suppl 2006;24:S22-S28.